Akero Therapeutics Inc (AKRO)

Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Research and Development	38.20% 53.39	38.63	27.98	21.79	18.32
Interest Income/Expense	1.01% 0.897	0.888	0.857	0.457	0.362
Operating Income/Loss	32.73% -61.87	-46.62	-35.63	-28.75	-25.42
Income/Loss From Continuing Operations Before Tax	39.15% -55.19	-39.66	-31.08	-25.83	-23.06
Income/Loss From Continuing Operations After Tax	39.15% -55.19	-39.66	-31.08	-25.83	-23.06
Net Income/Loss	39.15% -55.19	-39.66	-31.08	-25.83	-23.06
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	98.09% 1.0614	55.61	51.87	46.94	2.6205
Diluted Average Shares	98.09% 1.0614	55.61	51.87	46.94	2.6205
Basic Earnings Per Share	43.66% -1.02	-0.71	-0.60	-0.55	-0.42
Diluted Earnings Per Share	43.66% -1.02	-0.71	-0.60	-0.55	-0.42
Common Stock Dividends	-	-	-	-	-
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-